These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11918622)

  • 1. Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes.
    Colhoun HM; Thomason MJ; Mackness MI; Maton SM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Fuller JH;
    Diabet Med; 2002 Mar; 19(3):201-11. PubMed ID: 11918622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes.
    Thomason MJ; Colhoun HM; Livingstone SJ; Mackness MI; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Fuller JH;
    Diabet Med; 2004 Aug; 21(8):901-5. PubMed ID: 15270795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
    Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Mackness MI; Charlton-Menys V; Fuller JH;
    Lancet; 2004 Aug 21-27; 364(9435):685-96. PubMed ID: 15325833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.
    Diabetes Atorvastin Lipid Intervention (DALI) Study Group
    Diabetes Care; 2001 Aug; 24(8):1335-41. PubMed ID: 11473066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators.
    Wanner C; Krane V; Ruf G; März W; Ritz E
    Kidney Int Suppl; 1999 Jul; 71():S222-6. PubMed ID: 10412782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus.
    Croom KF; Plosker GL
    Drugs; 2005; 65(1):137-52. PubMed ID: 15610062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS; Goa KL
    Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
    Shepherd J; Barter P; Carmena R; Deedwania P; Fruchart JC; Haffner S; Hsia J; Breazna A; LaRosa J; Grundy S; Waters D
    Diabetes Care; 2006 Jun; 29(6):1220-6. PubMed ID: 16731999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of low-density lipoprotein cholestrol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial).
    März W; Wollschläger H; Klein G; Neiss A; Wehling M
    Am J Cardiol; 1999 Jul; 84(1):7-13. PubMed ID: 10404843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
    Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
    Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The collaborative atorvastatin diabetes study: preliminary results.
    Owen OG
    Int J Clin Pract; 2005 Jan; 59(1):121-3. PubMed ID: 15707477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.
    Arca M
    Drugs; 2007; 67 Suppl 1():43-54. PubMed ID: 17910520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
    LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
    N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
    Bakker-Arkema RG; Davidson MH; Goldstein RJ; Davignon J; Isaacsohn JL; Weiss SR; Keilson LM; Brown WV; Miller VT; Shurzinske LJ; Black DM
    JAMA; 1996 Jan; 275(2):128-33. PubMed ID: 8531308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trials.
    Hsue PY; Bittner VA; Betteridge J; Fayyad R; Laskey R; Wenger NK; Waters DD
    Am J Cardiol; 2015 Feb; 115(4):447-53. PubMed ID: 25637322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial.
    Holman RR; Paul S; Farmer A; Tucker L; Stratton IM; Neil HA;
    Diabetologia; 2009 Jan; 52(1):50-9. PubMed ID: 19002433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS).
    Hitman GA; Colhoun H; Newman C; Szarek M; Betteridge DJ; Durrington PN; Fuller J; Livingstone S; Neil HA;
    Diabet Med; 2007 Dec; 24(12):1313-21. PubMed ID: 17894827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS).
    Charlton-Menys V; Betteridge DJ; Colhoun H; Fuller J; France M; Hitman GA; Livingstone SJ; Neil HA; Newman CB; Szarek M; DeMicco DA; Durrington PN
    Clin Chem; 2009 Mar; 55(3):473-80. PubMed ID: 19147732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial.
    van Venrooij FV; van de Ree MA; Bots ML; Stolk RP; Huisman MV; Banga JD;
    Diabetes Care; 2002 Jul; 25(7):1211-6. PubMed ID: 12087021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.